Objective Doxorubicin-induced acute cardiotoxicity is associated with the Gly671Val (G671V; rs45511401) variant of multidrug resistance-associated protein 1 (MRP1). Doxorubicin redox cycling causes lipid peroxidation and generation of the reactive electrophile, 4-hydroxy-2-trans-nonenal (HNE). Glutathione forms conjugates with HNE, yielding an MRP1 substrate, GS-HNE, whose intracellular accumulation can cause toxicity.
Introduction
Cardiac toxicity is one of the most serious and well known adverse reactions related to the administration of doxorubicin and is dose dependent. Doxorubicin is one of the active components in a current standard treatment regimen for breast cancer. In 2004, approximately 189 000 women and men were diagnosed with breast cancer, according to the Centers for Disease Control and Prevention. On average, cardiac toxicity occurs in 5% of these cancer patients [1] , translating into more than 9000 cardiac toxicity cases and an annual death rate of almost 2000 patients in the US alone. Although doxorubicin cardiac toxicity is minimized by adherence to a maximum recommended dose of less than 400 mg/m 2 , it is noteworthy that cardiac toxicity is nevertheless observed in some populations receiving less than the maximum recommended dose [2] , suggesting genetic involvement of an unpredictable and idiosyncratic adverse drug reaction. In contrast, Allen [3] reported that doxorubicin is well tolerated in some patients receiving doses over twice that of the recommended total dose, stressing the significance of individual differences [4] . Thus, genetic or environmental factors that can influence drug concentrations may explain individual variations in both efficacy and safety. The cardiac toxicity of doxorubicin may be attributable in part to genetic variations in drug targets and/or genetic differences in drug disposition, such as in biotransformation enzymes and drug transporters [5, 6] .
Using polymerase chain reaction (PCR) single-strand conformation polymorphism analysis, Conrad et al. [7] identified several multidrug resistance-associated protein 1 (MRP1/ABCC1) variants in 36 healthy White volunteers. Among several variants, they identified Arg433Ser (R433S), located in the second transmembrane spanning domain, and Gly671Val (G671V; rs45511401), near the Walker A motif in the first nucleotide-binding domain. The R433S MRP1 variant showed a 50% decreased transport maximum for leukotriene C4 (LTC 4 ) [8] ; however, cells expressing this variant were more resistant to doxorubicin than those expressing wild-type (WT) MRP1 [8] . The G671V variant showed no difference in in-vitro transport assays using LTC 4 or estradiol-17b-glucuronide (E 2 17G) as substrates. Wang et al. [9] sequenced 142 individuals of four different populations (Chinese, Malay, Indian, and Whites) and found the frequencies of both of these single nucleotide polymorphisms (SNPs) to be less than 3%. The frequency of the G671V variant (exon 16, 2012G > T) was 2.78% for the T allele in Whites and 1.43% in the Indian population, with none reported in the Asian population [9] . Wang et al. [9] reported the functional effects of these nonsynonymous SNPs predicted by using SIFT, PolyPhen, and PANTHER to be potentially adverse. Importantly, in a nested case-control cohort clinical study, patients with the G671V variant showed a significantly increased doxorubicin-induced acute cardiac toxicity that accounted for 6.4% of the incidence of acute cardiac toxicity, with an odds ratio of 3.6 (95% confidence interval: 1.6-8.4) [10] . Whether this was due to an increased accumulation of intracellular doxorubicin or a decreased capacity for effluxing other MRP1 substrates is not known.
Upon administration, the quinone moiety of doxorubicin undergoes redox cycling and induces oxidative stress, which in turn initiates lipid peroxidation and the production of highly reactive lipid aldehydes, such as 4-hydroxy-2-trans-nonenal (HNE). HNE is detectable in heart tissues as early as 3 h after doxorubicin administration [11] [12] [13] [14] . HNE is an a,b-unsaturated aldehyde derived from o-6 polyunsaturated fatty acids, such as linoleic acid and arachidonic acid [15, 16] , and is one of the primary and highly toxic products of lipid peroxidation. HNE is a potent electrophile with high reactivity toward cellular nucleophiles. Protein residues known to react with HNE are cysteine, histidine, and lysine [15] , leading to the hypothesis that these products of lipid peroxidation play a central role in initiating functional impairment of the myocardium following treatment with doxorubicin. HNE also reacts with intracellular glutathione to form glutathione-conjugated HNE (GS-HNE) [17, 18] , which is less toxic than HNE, but still retains some toxicity [19, 20] , so that its clearance is warranted. Thus, metabolic removal of HNE could play an important role in protecting against myocardial injury.
Although several mechanisms are involved in doxorubicin-induced cardiac toxicity, oxidative damage appears to be the key component of such toxicity. In addition, on the basis of the fact that (a) cumulative doses of doxorubicin are a risk for doxorubicin-induced cardiac toxicity, (b) HNE and HNE metabolites (e.g. GS-HNE) have been shown to be associated with oxidative stress in a myocardial ischemic model [21] , and (c) MRP1 is highly expressed in the heart [22, 23] , we postulated that the association of the MRP1 G671V variant with doxorubicininduced acute cardiac toxicity [10] could be due to a change in its substrate specificity. In this study, we examined whether cells expressing the G671V and R433S variants versus WT MRP1 were more sensitive to doxorubicin, and characterized the transport properties of WT MRP1 relative to the G671V and R433S MRP1 variants, specifically with respect to GS-HNE transport activity. 
Materials and methods

Reagents
Vector construction and site-directed mutagenesis
The plasmid pCMV/MRP1 containing MRP1 cDNA was a generous gift from Dr Piet Borst (Division of Molecular Biology, the Netherlands Cancer Institute, Amsterdam, the Netherlands). For construction of an MRP1 expression vector containing a neomycin selectable marker, the MRP1 coding region was amplified by PCR using plasmid pCMV/MRP1 as a template and using two gene-specific primers (forward primer: 5 0 -GCGATATCATGGCGCTCC GGGGCTTCTGCAGCG-3 0 ; reverse primer: 5 0 -TATGCGG CCGCTCACACCAAGCCGGCGTCTTTGGCC-3 0 ). Two restriction enzyme sites, EcoRV and NotI, were included in the primers to facilitate cloning. The PCR products were purified using a PCR purification kit according to the manufacturer's instructions (Qiagen, Valencia, California, USA), digested with EcoRV and NotI, and purified on an agarose gel (Qiagen). The purified fragment was inserted into the corresponding sites of the plasmid pUSEamp( + ) (Millipore), which contains a neomycin selectable marker. MRP1 variants of G671V and R433S were generated using the QuickChange II XL site-directed mutagenesis kit (Stratagene, La Jolla, California, USA) according to the manufacturer's instructions with the following mutagenic primers (for G671V, forward primer: 5 0 -TCCATCCCCGAAGTTGCTTTGGTG GCCGTG-3 0 and reverse primer: 5 0 -CACGGCCACCAAAG CAACTTCGGGGATGGA-3 0 ; for R433S, forward primer: 5 0 -GTGGACGCTCAGAGCTTCATGGACTTGGC-3 0 and reverse primer: 5 0 -GCCAAGTCCATGAAGCTCTGAGCGT CCAC-3 0 ). MRP1 and MRP1 variants in expression constructs were sequenced in both forward and reverse directions to confirm the correct sequences (MWG, High Point, North Carolina, USA). HEK293 cells were transfected with expression vectors of WT MRP1, MRP1 variants, or an empty vector using a TransIT293 transfection reagent. Stable transfected cells were obtained after 10-14 days of selection with G418 (600 mg/ml). The stable transfected cells were tested for MRP1 expression by western blot analysis or immunofluorescent staining. Cells were maintained in culture media containing G418 (300 mg/ml) until use.
Flow cytometry
To quantify MRP1 expression in the transfected cell lines, cells were fixed with 2% paraformaldehyde for 10 min and then permeabilized in cold methanol for 20 min on ice. Cells were washed twice in fluorescence activated cell sorter buffer [2% fetal bovine serum in phosphate-buffered saline (PBS)] and stained with MRPr1 antibody (1 : 100) for 1 h at room temperature, washed twice, and incubated with AlexaFluor 488-conjugated secondary antibody (1 : 500) for 1 h at room temperature and protected from light. Samples were subjected to analysis using a flow cytometer (BD-LSR model, Becton-Dickinson, San Jose, California, USA). Twenty thousand events of live cells were analyzed for each sample. The strength of the fluorescence was depicted in terms of the mean fluorescence intensity. Flow cytometry studies were performed by the University of Kentucky Flow Cytometry Core Facility.
RNA isolation and real-time reverse transcriptase-PCR analysis of gene expression
Total RNA from transfected HEK293 cells was isolated using the GenElute Mammalian Total RNA Miniprep Kit from Sigma-Aldrich (Milwaukee, Wisconsin, USA). The cDNA was synthesized using SuperScript III Reverse Transcriptase from Invitrogen according to the manufacturer's instructions. Primers and UPL probes for real-time reverse transcriptase (RT)-PCR were designed and ordered from Roche Applied Science (Mannheim, Germany) using online software (http://www.universalprobelibrary.com), and realtime RT-PCR was determined using a 480 LightCycler (Roche Applied Sciences). For the detection of MRP1 mRNA, primers MRP1-F (TGTGGGAAAACACATCTTT GA) and MRP1-R (CTGTGCGTGACCAAGATCC) were used with UPL probe 89. For the detection of 18S RNA, primers 18S-F (CGATTGGATGGTTTAGTGAGG) and 18S-R (AGTTCGACCGTCTTCTCAGC) were used with UPL probe 81. In detail, 2 mg of total RNA was used for cDNA synthesis, and then the synthesized cDNA was diluted to 100 ml. Diluted cDNA (5 ml) was used as a template in a 20-ml reaction volume. The target gene expression was normalized by its 18S RNA gene expression.
Animals
FVB and Mrp1-disrupted FVB (Mrp1
-/ -; Taconic Transgenics, Hudson, New York, USA) mice were maintained in the Division of Laboratory Animal Resources facility and provided food and water ad libitum. All experiments were approved by and complied with the requirements of the Institutional Animal Care and Use Committee of the University of Kentucky. Mice were treated intraperitoneally with doxorubicin (20 mg/kg) and the heart was removed 24 h later.
Isolation of plasma membranes
Hearts were homogenized in buffer containing 0.225 mol/l mannitol, 0.075 mol/l sucrose, 1 mmol/l EGTA, and protease inhibitors (1 mmol/l phenylmethylsulfonyl fluoride, 1 mg/ml of leupeptin, 1 mg/ml of aprotinin, 1 mg/ml of pepstatin), centrifuged at 480g for 5 min, and the pellet was used to isolate sarcolemma as described [24] . Plasma membranes from HEK293 cells stably transfected with MRP1 and its variants were similarly prepared as described [24] .
Synthesis and purification of glutathione-conjugated 4-hydroxy-2-trans-nonenal [20] . The reaction was performed at 371C for 2 h or until the concentration of HNE remained stable, as monitored by the HNE absorbance at 224 nm. Unlabeled GS-HNE was generated by incubation of freshly prepared glutathione with HNE in a 4 : 1 molar ratio in the presence of 20 mmol/l of potassium phosphate buffer, pH 6.8, at 371C with gentle mixing [20] . The reaction mixtures were purified by high-performance liquid chromatography (HPLC) on a Symmetry C18, 4.6 Â 250 mm column (Waters Corporation Milford, Massachusetts, USA) using a linear gradient from 0 to 100% solvent B (0.05% trifluoroacetic acid in acetonitrile) in solvent A (0.05% trifluoroacetic acid in water) over 25 min at a flow rate of 1 ml/min. The column effluent was monitored at 210 nm, and peak fractions (retention time between 11 and 13 min) were collected, lyophilized, and redissolved in absolute ethanol. The concentration of GS-HNE was measured colorimetrically [20] .
Immunoblot analysis
Whole-cell lysate or plasma membrane protein samples were fractionated by SDS-polyacrylamide gel electrophoresis, 4-12% polyacrylamide gel, transferred onto a nitrocellulose membrane, and blocked with 5% nonfat dried milk in a Tris-buffered saline Tween-20 (TBS-T; 10 mmol/l of Tris-HCl, pH 7.8, 150 mmol/l of NaCl, and 0.1% Tween 20) buffer pH 7.8 for 1 h at room temperature. Membranes were incubated with the primary antibodies for MRP1 (1:1000) and Na + /K + -ATPase a1 (1:20 000), washed three times, each for 5 min with TBS-T, followed by incubation with the secondary antibody (1 : 5000) 1-2 h at room temperature, and finally washed twice with TBS-T buffer for 5 min. Proteins were detected using the enhanced chemiluminescence detection system (ECL Plus; Amersham Biosciences).
Fluorescent microscopy
HEK293-transfected cells were cultured to reach 80% confluence. Cell nuclei were stained with Hoescht 33342 and incubated at 371C for 5 min. Cells were washed with PBS, fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100, blocked with 1% BSA in PBS, incubated with primary antibody against MRP1 (1 : 2500), and probed with secondary antibodies (AlexaFluor 488 1 : 1000 in 1% BSA in PBS) as described [24] . Cells were washed, rinsed with ddH 2 O, air dried, mounting medium was added, and the cells were placed under a cover glass [24] . Images were taken using an Olympus IX71 fluorescent microscope (Olympus America, Melville, New York, USA).
Transport assays
The transport experiments were performed as described [24] . Sarcolemma or plasma membrane vesicles were prepared by vesiculation through a 25 G needle 15 times before the transport assay. ATP-dependent transport of [ 3 H]GS-HNE into plasma membrane vesicles (5 mg protein/20 ml) was measured in incubations at 371C for 1 min, whereas that of [ 3 H]LTC 4 was measured at 231C for 1 min [24, 25] . Reactions were terminated, filtered, and radioactivity sequestered within the inside-out vesicles detected as described [24] .
Cytotoxicity and doxorubicin retention assays
To determine cytotoxicity, cells (2.5 Â 10 4 /well) were seeded onto a 96-well plate and cultured in the presence of doxorubicin at various concentrations. After 45 h, 20 ml of methylthiazol tetrazolium (5 mg/ml) was added to each well and cultures were continued for an additional 3 h. Supernatants were discarded, 100 ml of dimethylsulfoxide was added to dissolve the formazan crystal, and its concentration was determined by spectrophotometry at A 540 . The methylthiazol tetrazolium values (absorption expressed as a percentage of control values) obtained after a continuous 48 h exposure of cells to doxorubicin were compared, and the doxorubicin concentrations inhibiting cell growth by 50% (IC 50 ) were calculated from the per cent survival curves.
To determine cellular retention of doxorubicin, cells (5 Â 10 5 /well) were plated and cultured in 24-well plates using 6 wells per cell line. After 24 h in culture, cells were treated with 50 mmol/l of doxorubicin for 1 h, the media were replaced with fresh media, and cells were incubated for an additional 30 min in the absence of doxorubicin. Cells were washed twice with PBS, 800 ml of buffer (50 mmol/l of Tris-HCl, pH 8.0, 150 mmol/l of NaCl, 1% NP-40, 0.5% deoxycholate, and 0.1% SDS) was added to each well to lyse cells, and 200 ml of cell lysate was assayed for doxorubicin by fluorescence spectroscopy (excitation at 460/40; emission at 560/15 nm). In a separate experiment in which the 30-min efflux step was excluded, cells (2.5 Â 10 5 /well) were plated and cultured for 24 h, treated with 1.5 mmol/l of doxorubicin, and cultured for an additional 24 h. Doxorubicin retained in cells was assessed as above, and retained GS-HNE was assessed as described below.
High-performance liquid chromatography assay of glutathione, glutathione disulfide, and glutathioneconjugated 4-hydroxy-2-trans-nonenal Cells were treated with doxorubicin (0.5 or 1.5 mmol/l) for 0, 4, 24, or 48 h as indicated in the figure legends, and glutathione, glutathione disulfide (GSSG), and GS-HNE were quantified by HPLC. Cells were washed once with PBS and harvested by trypsinization. Pellets were washed three times in cold PBS, resuspended in cell lysis buffer (1% Triton X-100, 0.2 mol/l NaCl, 0.1 mol/l Tris-HCl with Complete Mini protease inhibitor), incubated on ice for 20 min, and centrifuged at 4000g at 41C for 5 min. For GS-HNE analysis, supernatants were subjected directly to HPLC analysis using the same conditions as those described for the synthesis and purification of GS-HNE. For glutathione and GSSG quantification, whole-cell lysates were used for glutathione derivatization as described [26] , with minor modifications. Five percent trichloroacetic acid, 7.5 mmol/l of N-ethylmaleimide, and 100 mmol/l of dithiotheitol were prepared in redox quenching buffer (20 mmol/l of HCl, 5 mmol/l of diethylenetriaminepentaacetic acid, and 10 mmol/l of ascorbic acid) [26] . Monobromobimane (50 mmol/l) was dissolved in HPLC-grade acetonitrile-triethanolamine (1 mol/l, pH 8.2). The monobromobimane-derivatized samples were centrifuged and the supernatant was assayed for thiol-bimane fluorescence by reverse-phase HPLC using a linear gradient from 0 to 100% solvent B (50% methanol, 0.25% acetic acid in water) in solvent A (10% methanol, 0.25% acetic acid in water) over 28 min at a flow rate of 0.8 ml/min with fluorescence detection at Ex 370 /Em 485 using the Waters 2475 Multi l fluorescence detector as described [26] . Fluorescence intensities versus time of elution were quantified using Waters Breeze chromatography software v. 3.2 (Waters Corporation Milford) and peak areas were integrated and converted to nmol glutathione equivalents from the integrated areas under the glutathione standard curve.
Statistical analysis
Data of quantitative results were expressed as mean ± SEM, or as otherwise indicated. Statistical analyses were performed using one-way analysis of variance, followed by a post-hoc test using GraphPad Prism 4 (GraphPad Software, San Diego, California, USA). A P value of less than 0.05 was considered as a significant difference. IC 50 values were obtained by nonlinear regression analysis to obtain the best-fit values and the 95% confidence interval Patients with the G671V variant showed a significantly increased doxorubicin-induced acute cardiac toxicity [10] . In an attempt to understand this phenomenon, we developed HEK293 cell lines that stably expressed human MRP1 SNPs G671V, and three different control cells: HEK293 cells transfected with pUSEamp(+) vector (HEK pUSE ), WT MRP1 (HEK MRP1 ), or the R433S variant (HEK R433S ), which is not associated with doxorubicininduced acute cardiac toxicity. To confirm MRP1 expression and localization, we immunostained the cells for MRP1 as shown in Fig. 1 ; whereas HEK pUSE did not express MRP1, the WT and MRP1 variants showed high MRP1 protein expression in the plasma membrane (Fig. 1a) . The expression levels of MRP1 did not differ among the MRP1-transfected cells lines with respect to either protein or mRNA level, as measured by flow cytometry (Fig. 1b) and RT-PCR (Fig. 1c) , respectively.
To determine the impact of the G671V SNP on cell viability and to estimate the doxorubicin IC 50 value, we cultured cells in the presence of doxorubicin at various concentrations for 48 h (Fig. 2a) ; IC 50 values were calculated from the percent survival curves (Fig. 2b) . As shown in Fig. 2a , HEK G671V cells were more sensitive to doxorubicin than HEK MRP1 cells, whereas HEK R433S cells were not significantly different from HEK MRP1 cells (Fig. 2b) . All three MRP1-overexpressing cells were more resistant to doxorubicin than HEK pUSE control cells.
HEK G671V cells retain more doxorubicin and glutathioneconjugated 4-hydroxy-2-trans-nonenal than HEK MRP1 and HEK R433S cells
The cytotoxicity of doxorubicin is dependent on its intracellular cumulative concentration, and is decreased by MRP1-dependent efflux. To determine whether the G671V variant influenced retention of doxorubicin, we incubated cells with doxorubicin (50 mmol/l, 1 h) and then cultured cells for an additional 30 min in the absence of doxorubicin to determine its MRP1-mediated efflux. We also incubated cells with 1.5 mmol/l of doxorubicin for 24 h and then measured intracellular doxorubicin to determine doxorubicin retention at steady state. Following a 1 h-incubation, HEK G671V cells retained 20% more doxorubicin, whereas HEK R433S cells retained significantly less doxorubicin compared with HEK MRP1 cells (Fig. 3a) . There was no difference in doxorubicin retention following the 24-h incubation between HEK G671V and HEK MRP1 (Fig. 3b) . As expected, the highest doxorubicin accumulation occurred in HEK pUSE cells. Interestingly, doxorubicin retention in HEK R433S was less than that in HEK MRP1 cells following both 1 and 24 h of incubation ( Fig. 3a and b) . Doxorubicin initiates reactive oxygen species and causes lipid peroxidation, with HNE as one of the major toxic lipid metabolites. The highly electrophilic HNE reacts rapidly with nucleophiles, particularly glutathione, to form GS-HNE. Despite its decreased reactivity, GS-HNE remains toxic and requires an efflux transporter to eliminate it from cells [20] . We therefore characterized the retention of GS-HNE in HEK pUSE , HEK MRP1 , HEK G671V , and HEK R433S cells following treatment with 1.5 mmol/l of doxorubicin for 24 h. As shown in Fig. 3c , treatment with doxorubicin significantly increased GS-HNE in both HEK pUSE and HEK G671V cells, and GS-HNE retention was significantly greater in HEK G671V than in HEK MRP1 or HEK R433S cells (Fig. 3d) .
HEK G671V cells have decreased glutathione/glutathione disulfide ratios compared with HEK MRP1 cells
Glutathione is an important antioxidant in protecting cells from oxidative damage so that a decrease in the glutathione/GSSG ratio provides a measure of the degree of oxidative stress in cells, which is associated with cardiovascular diseases [27] . To determine whether the decreased doxorubicin IC 50 in HEK G671V was due to more severe oxidative stress, we measured intracellular glutathione and GSSG and calculated the glutathione/GSSG ratios in cells cultured in media alone or in the presence of doxorubicin (0.5 mmol/l) for 4, 24, and 48 h. Glutathione and GSSG were the highest in HEK pUSE and the lowest in HEK G671V at all time points after doxorubicin treatment, whereas glutathione and GSSG were similar in HEK MRP1 and HEK R433S cells at all time points (Fig. 4a  and b) . The glutathione/GSSG ratio in HEK MRP1 was well maintained throughout doxorubicin exposure, but was higher in HEK R433S up to 24 h (Fig. 4c, inset) . Consistent with their decreased doxorubicin IC 50 , the glutathione/GSSG ratio in HEK G671V was lower than all other cell lines at all time points of doxorubicin exposure (Fig. 4c) , and was significantly decreased at 48 h after doxorubicin (Fig. 4c, inset) .
To determine whether augmenting intracellular glutathione might increase cell survival in HEK G671V cells treated with doxorubicin, we supplemented these cells with glutathione or GEE, a glutathione prodrug. Supplementation of the culture media with GEE for 48 h significantly increased intracellular glutathione levels in HEK G671V in a dose-dependent manner (Fig. 5a ), but did not increase cell survival following treatment with doxorubicin (0.5 mmol/l, 48 h; Fig. 5b ). However, inhibition of MRP1 with MK571 further reduced the percent survival of HEK G671V , regardless of supplementation of the media with glutathione or GEE (Fig. 5b) . These data further supported the importance of MRP1 transport activity in protecting cells against doxorubicin-induced toxicity. 
G671V single nucleotide polymorphism maintains LTC 4 transport activity but loses glutathione-conjugated 4-hydroxy-2-trans-nonenal transport capacity
In view of the cellular GS-HNE retention in HEK G671V cells, we examined further whether the MRP1 polymorphisms would have an impact on their substrate specificity or transport capacity. We first characterized transport of the classic MRP1 substrate, LTC 4 , in plasma membrane vesicles after normalization for expression of MRP1 (Fig. 6a) . The G671V variant was comparable with WT MRP1 with respect to LTC 4 transport, whereas LTC 4 transport was decreased by 75% in the R433S variant compared with WT MRP1 (Fig. 6b) , consistent with previous reports [7, 8] . To determine whether the G671V variant might have an altered dependence on glutathione for transport, we examined the effects of glutathione; 0.5 mmol/l of glutathione had no effect on transport, whereas 5 mmol/l of glutathione completely inhibited LTC 4 transport by MRP1 and both its variants (Fig. 6b) .
We next determined the kinetic parameters for GS-HNE transport in plasma membrane vesicles. GS-HNE was transported by Michaelis-Menten kinetics (Fig. 6c) , and showed a markedly reduced transport by the G671V variant such that the V max was decreased to about 15% of that by WT MRP1 (Fig. 6c) . In contrast, the V max of the R433S variant was increased over two-fold relative to WT MRP1. The K m value of the G671V variants did not differ significantly from that of WT MRP1 (Fig. 6c) , and agreed well with the K m of 1.6 mmol/l reported previously for MRP1 [20] . The estimate of the K m for the R433S variant was higher (Z 6 mmol/l), consistent with its increased V max (Fig. 6c) . The V max /K m of the G671V variant was only about 10% (0.025 mg/l/min) of that of WT MRP1 (0.24 mg/l/min), indicating a markedly decreased transport efficiency of the G671V variant.
Mrp1 is a major transporter for glutathione-conjugated 4-hydroxy-2-trans-nonenal in mouse heart
The loss of MRP1-mediated GS-HNE transport could be significant if this transporter were the main mechanism for the heart to eliminate GS-HNE. To investigate whether the cardiac sarcolemma can transport GS-HNE, and the 
MRP1 G671V decreases GS-HNE transport
importance of Mrp1, we isolated sarcolemma membranes from FVB WT and Mrp1 -/ -mice that were treated with doxorubicin (20 mg/kg, intraperitoneally) and killed 24 h later. As shown in Fig. 7 , sarcolemma from FVB mice transported GS-HNE in a saturable manner, with a K m and V max of 2.5 ± 1.1 mmol/l and 911 ± 166 pmol/min/mg protein, respectively. Transport of GS-HNE was not detectable in sarcolemma vesicles prepared from Mrp1 -/ -mice (Fig. 7) , indicating that Mrp1 was the sole transporter mediating GS-HNE transport.
Discussion
The increased incidence of acute doxorubicin-induced cardiac toxicity in patients who carry the G671V variant of MRP1 suggests that the glycine to valine variant at amino acid 671 of MRP1 affects its transport function for certain substrates. Consistent with this hypothesis is the result predicted by PolyPhen-2 (http://genetics.bwh.harvard.edu/ pph2/), in which this G671V variant is predicted to be 'probably damaging', likely due to the proximity of G671 to the Walker A motif. The present studies provided clear evidence that the ability to transport GS-HNE was markedly decreased by 85% in the G671V MRP1 variant relative to WT MRP1. In a previous study [7] , the G671V variant did not show altered transport of several MRP1 substrates (LTC 4 , estrone sulfate, and E 2 17G), and in this study, we confirmed that transport of LTC 4 was not impacted. These data further support our understanding of the differential effects of changes in amino acid sequence on transport characteristics of various substrates for MRP1, and other MRP transporters [28] [29] [30] . Characterization of the doxorubicin IC 50 values revealed that among MRP1-expressing cell lines, HEK G671V cells were the most sensitive to its cytotoxic effects (Fig. 2) . HEK G671V retained about 20% more doxorubicin than did HEK MRP1 and HEK R433S (Fig. 3a) , and this could contribute to the decreased doxorubicin IC 50 from 463 nmol/l in HEK MRP1 to 181 nmol/l in HEK G671V . In contrast, HEK R433S cells retained less doxorubicin than HEK MRP1 cells, but these two cell lines did not differ in their IC 50 values. These data are in contrast with an earlier report [8] showing that HeLa cells expressing R433S are two-fold more resistant than cells expressing WT MRP1. The bases for the different findings are not known, but likely reflect the use of different cell lines. As expected, HEK pUSE cells retained the greatest amount of doxorubicin and were the most sensitive to doxorubicin-induced cytotoxicity.
We next examined cellular GS-HNE levels after treatment of cells with 1.5 mmol/l of doxorubicin for 24 h and found that HEK G671V cells retained the highest amount of this MRP1 substrate. We also measured the redox status of glutathione and GSSG in each of the cell lines in response to doxorubicin treatment. Glutathione and GSSG were the highest in HEK pUSE cells, consistent with the known glutathione-efflux and GSSG-efflux activities of MRP1. Glutathione and GSSG levels decreased across time following doxorubicin exposure in all cell lines, and were the lowest at all time points in HEK G671V cells. The loss of glutathione exceeded that of GSSG, so that the glutathione/GSSG ratio was also the lowest at all time points in HEK G671V cells, indicating that these cells were under the most oxidative stress. In view of the lack of effect of glutathione supplementation on the viability of HEK G671V cells in the presence of doxorubicin, and their further decreased survival in the presence of the MRP1 inhibitor MK571, we characterized the GS-HNE transport capacity of the WT and variant forms of MRP1. On the basis of V max values, the GS-HNE transport capacity of the G671V variant was decreased 85% relative to WT MRP1 (Fig. 6c) , and exhibited a 10-fold decrease in V max /K m . These data imply that GS-HNE accumulated in HEK G671V cells due to the loss of MRP1 efflux activity. It is important to note that GS-HNE remains toxic to cells [20] , most likely because it mediates feed-back inhibition of glutathione-S-transferases that catalyze the conjugation of glutathione and HNE, resulting in the accumulation of HNE and an attendant cytotoxicity [31] . Alternatively, but with lesser likelihood, Schiff base formation between GS-HNE and Lys residues on proteins could also play a role in its toxicity [15, 16] .
These data are consistent with the decreased survival of HEK G671V cells in the presence of MK571, a classic MRP inhibitor, despite increased intracellular concentrations of glutathione induced by incubation with GEE (Fig. 5a ). The present data also indicate the importance of MRP1 in effluxing GS-HNE from the heart, as sarcolemma membrane vesicles from mice deficient in Mrp1 showed no GS-HNE transport activity (Fig. 7) . These data are consistent with the early identification of an efflux mechanism in the heart for GS-HNE [32] . These are the first data demonstrating that the G671V variant has a decreased capacity to efflux GS-HNE, despite retention of the ability of this MRP1 variant to transport other classic MRP1 substrates, that is, LTC 4 , estrone sulfate, and E 2 17G [7] . It is also interesting to note that the R433S variant showed significantly increased transport of GS-HNE, despite decreased transport of LTC 4 ( Fig. 6b ) and estrone sulfate, and unaltered transport of E 2 17G [8] . Systematic mutation of amino acid residues in MRP1 has provided numerous examples demonstrating selective alteration of transport of substrates [33, 34] . In a study comparing the substrate specificities of MRP1 and MRP3, Grant et al. [30] substituted amino acids 425-516 of MRP1 in the region spanning transmembrane helices 8 and 9 with those of amino acids 411-502 of MRP3, and found complete loss of LTC 4 transport, but a modest enhancement in E 2 17bG transport, with minimal effects on transport of methotrexate, a substrate common to both MRP1 and MRP3 [30] . A cluster of three amino acids (Tyr440, Ile441, and Met443) in MRP1 and Phe426, Leu427, and Leu429 of MRP3 made major contributions to these differences. The conclusion of these authors that amino acids in this region of MRP1/MRP3 make significant contributions to substrate specificity is consistent with the current findings that the Arg433 of MRP1 also selectively influenced MRP1 substrate specificity. Interestingly, alignment of this region of MRP1 (Fig. 2 of [29] ) shows that Arg433 of MRP1 is conserved in MRP3, MRP5, MRP6, and MRP7, and is replaced with a lysine in MRP2 and MRP4, suggesting the importance of a cationic amino acid in this position.
Gly671 is seven amino acids upstream of the Walker A motif of NBD1 in MRP1, and is conserved in CFTR, TAP1, YCF1, and some bacterial ABC transporters [33] , again implying an important function. Despite being located close to the Walker A motif, the substitution of a valine must not have affected the rate of ATP hydrolysis, on the basis of the retention of LTC 4 transport.
In conclusion, cells expressing the G671V MRP1 variant were more sensitive to doxorubicin than cells expressing WT MRP1, most likely due to an increase in the accumulation of intracellular GS-HNE, together with a decrease in the glutathione/GSSG ratio, indicating oxidative stress that can lead to cytotoxicity. Although increased retention of doxorubicin could also contribute to the increased oxidative stress in cells expressing the G671V variant, because amino acids in the third membrane spanning domain, especially between amino acids 959 and 1187, are considered most critical for doxorubicin transport [35] , it seems less likely that the G671V variant alters MRP1 recognition of doxorubicin. The decreased GS-HNE transport capacity of the G671V variant further indicates that MRP1 polymorphisms can play a significant role in MRP1 activity, and that these findings may be clinically important in patients receiving chemotherapy, particularly doxorubicin. Close monitoring for cardiac toxicity may therefore be beneficial in patients with the MRP1 G761V polymorphism who are receiving doxorubicin chemotherapy.
